Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAPOLI 3: Irinotecan Liposome Injection in Previously Untreated Metastatic Pancreatic Cancer
NCT04083235Phase 3Completed
- Sponsor
- Ipsen
- Start
- Feb 2020
- Primary completion
- Jul 2022
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of nanoliposomal irinotecan in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Ipsen. Primary endpoint: Overall Survival at 893 days. Started Feb 2020; status: completed.
02
Drugs
nanoliposomal irinotecan
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04083235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04083235.